Varie
Bavarian Nordic Submits a Marketing Application for its Smallpox Vaccine to the European Medicines Agency
Bavarian Nordic A/S (OMX: BAVA) announced today that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its smallpox vaccine (IMVAMUNE ) that will be marketed under the trade name IMVANEX in Europe. The MAA has been filed for consideration under the centralized procedure and following a successful review could potentially lead to the market authorization of IMVANEX in Europe (EAA countries) during 2013.
If found acceptable by EMA, IMVANEX will be indicated for active immunization against smallpox infection and disease in persons 18 years of age and older. The indication will include individuals with immune deficiencies and skin disorders such as those who are Human Immunodeficiency Virus (HIV) infected and those diagnosed with Atopic Dermatitis (AD).
This submission to EMA follows the New Drug Submission (NDS) filed with Health Canada during 2011, which is currently undergoing the review process and still expected to result in a market approval for IMVAMUNE in Canada during 2012.
" " stated Anders Hedegaard, President & CEO of Bavarian Nordic.
Asger Aamund
Chairman of the Board
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
IMVAMUNE is positioned as a new and superior third-generation smallpox vaccine for protection of the general population (18-55 years old). The likely use of IMVAMUNE by governments would include: individuals contraindicated for conventional smallpox vaccines: e.g. individuals with HIV, people with atopic dermatitis (AD) and members of their households: First-line responders (military, police, health care workers, etc.) and the general population.
IMVAMUNE has fast-track status with the US authorities and has completed clinical Phase 2 development. Although unlicensed, the vaccine is already in production and available for governments globally under their national emergency rules, due to the need for a safer smallpox vaccine.
In clinical trials to date, more than 3,400 individuals have been vaccinated with IMVAMUNE , which has demonstrated a favourable safety profile. The vaccinated subjects include almost 1,000 individuals with compromised immune systems who are currently ineligible for conventional smallpox vaccines.
The development of IMVAMUNE is funded by the US government through contracts with BARDA (Biomedical Advanced Research and Development Authority) and the NIH (National Institutes of Health).
Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company's lead program is PROSTVAC , a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC has been tested in nearly 600 patients. In infectious diseases, the company's lead program is IMVAMUNE , a third-generation smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. For more information, visit www.bavarian-nordic.com
This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Copyright Thomson Reuters
Attachment(s)
http://hugin.info/100065/R/1590315/499579.pdf
Regulatory News
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: %s via Thomson Reuters ONE